Duration of protection after first dose of acellular pertussis vaccine in infants

Pediatrics

Volumn 133, Issue 3, 2014, Pages

  Quinn, Helen E ^a   Snelling, Thomas L ^b   Macartney, Kristine K ^a   McIntyre, Peter B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Effectiveness; Immunization; Pertussis; Vaccine; Waning

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ARTICLE; AUSTRALIA; BORDETELLA PERTUSSIS; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GROUPS BY AGE; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; PERTUSSIS; PRIORITY JOURNAL; REGISTER; SENSITIVITY ANALYSIS; VACCINATION;

EFFECTIVENESS; IMMUNIZATION; PERTUSSIS; VACCINE; WANING;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; IMMUNIZATION; INFANT; MALE; POPULATION SURVEILLANCE; TIME FACTORS; WHOOPING COUGH;

EID: 84895165195     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3181     Document Type: Article

References (36)

1. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, JAMA. 2012;308(20):2126-2132
2. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012-1019
3. Bisgard KM, Rhodes P, Connelly BL, et al; Centers for Disease Control and Prevention. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics. 2005;116(2). Available at: www.pediatrics.org/cgi/content/full/116/2/e285
4. Juretzko P, von Kries R, Hermann M, Wirsing von König CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis. 2002;35(2):162-167
5. Hviid A, Stellfeld M, Andersen PH, Wohlfahrt J, Melbye M. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine. 2004;22(27-28):3530-3534 (Pubitemid 39099630)
6. Campbell H, Amirthalingam G, Andrews N, et al. Accelerating control of pertussis in England and Wales. Emerg Infect Dis. 2012;18(1):38-47
7. Salmaso S, Eurosurveillance Editorial team. Pertussis vaccine schedules across Europe. Eurosurveillance 2004;8(41):pii=2567
8. Octavia S, Sintchenko V, Gilbert GL, et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008 -2010. J Infect Dis. 2012;205(8):1220-1224
9. Kallonen T, He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines. 2009;8(7):863-875
10. NNDSS Annual Report Writing Group. Australia's notifiable disease status, 2010: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell. 2012;35(1):1-69
11. Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995-2005 - trends by region and age group. Commun Dis Intell Q Rep. 2007;31(2):205-215
12. National Health and Medical Research Council. The Australian Immunisation Handbook. Canberra, Australia: Australian Government Department of Health and Ageing; 2003
13. Quinn HE, McIntyre PB. The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bull World Health Organ. 2011;89(9):666- 674
14. Efficacy of pertussis vaccination in England. Report from the PHLS Epidemiological Research Laboratory and 21 area health authorities. Br Med J (Clin Res Ed). 1982;285(6338):357-359
15. Salmaso S, Mastrantonio P, Tozzi AE, et al; Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001;108(5). Available at: www.pediatrics.org/cgi/content/full/108/5/E81
16. Australian Government Department of Health and Ageing. National Notifiable Diseases Surveillance System. Number of notifications of pertussis, Australia, in the period of 1991 to 2008. 2009. Available from: http://www9.health.gov.au/cda/Source/Rpt-3.cfm
17. Allen CJ, Ferson MJ. Noti fication of infectious diseases by general practitioners: a quantitative and qualitative study. Med J Aust. 2000;172(7):325-328 (Pubitemid 30202878)
18. Spokes PJ, Quinn HE, McAnulty JM. Review of the 2008 -2009 pertussis epidemic in NSW: notifications and hospitalisations. N S W Public Health Bull. 2010;21(7- 8):167-173
19. Hull B, Dey A, Mahajan D, Menzies R, McIntyre PB. Immunisation coverage annual report, 2009. Commun Dis Intell Q Rep. 2011;35(2):132 -148
20. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M; German Breast Cancer Study Group (GBSG). Modelling the effects of standard prognostic factors in nodepositive breast cancer. Br J Cancer. 1999;79(11-12):1752 -1760
21. McIntyre PB, Sintchenko V. The "how" of polymerase chain reaction testing for Bordetella pertussis depends on the " why". Clin Infect Dis. 2013;56(3):332-334
22. Foxwell AR, McIntyre P, Quinn H, Roper K, Clements MS. Severe pertussis in infants: estimated impact of first vaccine dose at 6 versus 8 weeks in Australia. Pediatr Infect Dis J. 2011;30(2):161 -163
23. Shinall MC Jr, Peters TR, Zhu Y, Chen Q, Poehling KA. Potential impact of acceleration of the pertussis vaccine primary series for infants. Pediatrics. 2008;122(5):1021-1026
24. Hull B, Dey A, Menzies R, Brotherton J, McIntyre PB. Immunisation coverage annual report, 2011. Commun Dis Intell. 2013;37: (in press)
25. European Centre for Disease Prevention and Control. Vaccine schedule. 2013
26. Torvaldsen S, Simpson JM, McIntyre PB. Effectiveness of pertussis vaccination in New South Wales, Australia, 1996-1998. Eur J Epidemiol. 2003;18(1):63-69 (Pubitemid 36401837)
27. McCallum LK, Liu B, McIntyre P, Jorm LR. Estimating the burden of pertussis in young children on hospitals and emergency departments: a study using linked routinely collected data. Epidemiol Infect. 2013:1-11. Epub May 15
28. Jardine A, Conaty SJ, Lowbridge C, Staff M, Vally H. Who gives pertussis to infants? Source of infection for laboratory con firmed cases less than 12 months of age during an epidemic, Sydney, Commun Dis Intell Q Rep. 2010;34(2):116-121
29. de Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010;50(10):1339-1345
30. Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine. 2013;31(4):618-625
31. Cherry JD. Why do pertussis vaccines fail? Pediatrics. 2012;129(5):968-970
32. Kaczmarek MC, Valenti L, Kelly HA, Ware RS, Britt HC, Lambert SB. Sevenfold rise in likelihood of pertussis test requests in a stable set of Australian general practice encounters, 2000-2011. Med J Aust. 2013;198(11):624-628
33. Hallander HO, Ljungman M, Storsaeter J, Gustafsson L. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS. 2009;117(11):797-807
34. Wood N, Marshall H, McIntyre P. Waning of pertussis antibodies to 4 years among infants who did and did not receive monovalent acellular pertussis vaccine at birth. In: 13th National Immunisation Conference; June 19-21, 2012; Darwin, Australia
35. Campbell P, McIntyre P, Quinn H, Hueston L, Gilbert GL, McVernon J. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS ONE. 2012;7(4):e35874
36. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP), MMWR Morb Mortal Wkly Rep. 2011;60(41):1424- 1426